Navigation Links
Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
Date:10/9/2008

SKOKIE, Ill., Oct. 9 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, announced today that Robert J. De Vaere has joined the Company as executive vice president and chief financial officer.

"Bob is an experienced executive who brings more than 28 years of financial management experience to Horizon, including the last decade in healthcare with both public and private companies," said Timothy P. Walbert, president and chief executive officer. "During his career, Bob has been instrumental in numerous M&A transactions as well as an IPO and will be an important part of Horizon's future growth."

Mr. De Vaere's most recent position was as senior vice president, finance and administration and chief financial officer of IDM Pharma, Inc. (Nasdaq: IDMI), a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer. Additionally, Mr. De Vaere served as vice president, finance and administration and chief financial officer of IDM Pharma from August 2005 to March 2006, and was vice president and chief financial officer of Epimmune from May 2000 until the business combination with IDM Pharma in August 2005.

Mr. De Vaere has also served as chief financial officer of Nexa Orthopedics, which was acquired by Tornier, Inc. and vice president of finance and administration and chief financial office of Vista Medical Technologies, Inc., a medical device company.

Earlier in his career, Mr. De Vaere held accounting, finance and administrative positions within the electronics and aerospace industries. Mr. De Vaere received a bachelor's degree from the University of California, Los Angeles.

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance. For more information about the company and its products, please visit http://www.horizontherapeutics.com.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Out beyond the horizon
2. Out beyond the horizon
3. BioHorizons Announces Agreement to Purchase Implant Logic Systems
4. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
5. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
6. BioHorizons Announces the Purchase of Implant Logic Systems
7. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
8. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
9. Horizon Therapeutics to Present at UBS Global Life Sciences Conference
10. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017   VWR ... provider of product and service solutions to ... it has acquired EPL Archives, Inc., an ... across the entire regulated product research, development ... document storage and ancillary services. EPL Archives ...
(Date:3/22/2017)... ... March 21, 2017 , ... Aqua Design Innovations ... goal and raising over $30,000 in the first 40 minutes of crowdfunding. EcoQube ... herbs fast, easy, and affordably, anywhere. , “Simply add fertilized water and in ...
(Date:3/22/2017)... ... March 22, 2017 , ... March 22, 2017...Council for ... another green revolution, one that utilizes technological innovation in smart, sustainable ways. Humans depend ... life such as aesthetics and environmental stability. This paper is the first in a ...
(Date:3/20/2017)... ... March 20, 2017 , ... SSCI and Whitehouse Laboratories, divisions of ... 2017 ! Sponsored by the Parenteral Drug Association (PDA), the New York Interphex ... industry professionals in attendance and more than 625 exhibitors, the educational and networking opportunities ...
Breaking Biology Technology:
(Date:3/9/2017)... , March 9, 2017 4Dx has ... World Lung Imaging Workshop at the University of Pennsylvania. ... invited to deliver the latest data to world leaders ... event brings together leaders at the forefront of the ... lung imaging. "The quality of the ...
(Date:3/7/2017)... 2017   HireVue , the leading provider of ... the best talent, faster, today announced the additions of ... and Diana Kucer as Chief Marketing Officer ... team poised to drive continued growth in the company,s ... of record bookings in 2017. "Companies worldwide ...
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
Breaking Biology News(10 mins):